COVID19 News

When the global mpox outbreak began in May 2022, various health agencies quickly authorized a vaccine to be administered based on historical clinical data.
However, those vaccine effectiveness decisions may have been premature compared to new real-world data.
The U.S. Centers for Disease Control and Prevention (CDC) recently confirmed a cluster of mpox cases in greater Chicago, Illinois.
And more than 50% of the new mpox cases in Chicago were in previously vaccinated people. 

While the U.S. Centers for Disease Control and Prevention (CDC) recently confirmed Dengue viruses are a risk in many parts of Central and South America, Mexico, and the Caribbean, the state of Texas could be added to the list.
As of early May 2023, the Texas Department of State Health Services (DSHS) reported its initial locally-acquired Dengue patient.

A clinical-stage synthetic biology company with a rational virus design platform for viral vaccines and immuno-oncology therapeutics today announced that it has initiated dosing in a pediatric Phase 1 study evaluating CodaVax™-RSV, a live-attenuated, intranasal vaccine candidate for the prevention of disease caused by the Respiratory Syncytial Virus (RSV).

The U.S. Department of Agriculture recently issued a Conditional Licensure for a novel oral vaccine against the wildlife spread of Borrelia burgdorferi, the bacterium responsible for Lyme disease.
Announced by US Biologic, Inc. on May 9, 2023, this innovative Borrelia Burgdorferi Bacterin vaccine is spray-coated onto pellets that mice consume.
As the expression goes, if you give a mouse a vaccine….. good things happen!
The only known vector of Lyme disease is blacklegged ticks, which are infected primarily by feeding on mammals, particularly white-footed mice. 

As the COVID-19 pandemic continues to fade away, researchers believe it is critical to understand the impact of vaccination type on neutralizing antibody response durability and identify individual difference factors related to the decline in neutralization.
Published by Scientific Reported on May 9, 2023, researchers reviewed immune response data measured by how many antibodies the body produces following vaccination with an authorized COVID-19 vaccine.

According to new data, the U.S. government and various countries may have prematurely ended their Mpox outbreak activity.
Recent Mpox outbreaks in Chicago, Paris, and Seoul indicated Mpox resurged in 2023.
The U.S. Centers for Disease Control and Prevention (CDC) forewarned in April 2023 that if Mpox reintroduction occurs and no additional vaccination or sexual behavior adaptations arise, the risk of a Mpox resurgence was greater than 35% in most jurisdictions in the U.S.